
Pharvaris B.V. (PHVS) Stock Forecast & Price Target
Pharvaris B.V. (PHVS) Analyst Ratings
Bulls say
Pharvaris is a late-stage biopharmaceutical company focused on developing novel oral bradykinin B2 receptor antagonists for the treatment of hereditary angioedema (HAE). The company's lead candidate, deucrictibant, has shown positive data in Phase 2 studies for both prophylaxis and on-demand treatment of HAE attacks, and the company is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks. With strong data supporting the efficacy and safety of deucrictibant, and a clear path towards potential regulatory approval, Pharvaris has the potential to be a leader in the HAE treatment market.
Bears say
Pharvaris is a late-stage biopharmaceutical company that is pursuing a clinically therapeutic target with small molecules for the treatment of hereditary angioedema (HAE). Despite positive data in both Phase 2 studies and promising results in the ongoing pivotal Phase 3 studies, Pharvaris's stock price may be dampened by a competitive landscape in the HAE market and a delayed launch timeline for their drug deucrictibant, which may impact their potential peak annual revenues, estimated to be around $600 million. Additionally, there may be financial concerns regarding the company's operating expenses, which were higher than expected in the last quarter.
This aggregate rating is based on analysts' research of Pharvaris B.V. and is not a guaranteed prediction by Public.com or investment advice.
Pharvaris B.V. (PHVS) Analyst Forecast & Price Prediction
Start investing in Pharvaris B.V. (PHVS)
Order type
Buy in
Order amount
Est. shares
0 shares